Mefenorex

Mefenorex
Clinical data
Trade names	Rondimen, Pondinil, Anexate
ATC code	A08AA09 (WHO) ;
Legal status
Legal status	BR: Class B2 (Anorectic drugs); CA: Schedule I; DE: Anlage II (Authorized trade only, not prescriptible);
Identifiers
	IUPAC name 3-chloro-N-(1-methyl-2-phenylethyl)propan-1-amine;
CAS Number	17243-57-1 ;
PubChem CID	21777;
ChemSpider	20467 ;
UNII	K98M4N387W;
KEGG	D07891 ;
CompTox Dashboard (EPA)	DTXSID6057665 ;
ECHA InfoCard	100.037.511
Chemical and physical data
Formula	C12H18ClN
Molar mass	211.73 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES ClCCCNC(Cc1ccccc1)C;
	InChI InChI=1S/C12H18ClN/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,8-10H2,1H3 ; Key:XXVROGAVTTXONC-UHFFFAOYSA-N ;
	(verify)

Mefenorex (marketed as Rondimen, Pondinil, Anexate) is an amphetamine derivative with a relatively mild psychostimulant profile. Developed in the 1960s, it was used throughout the 1970s as an appetite suppressant for treating obesity. Mefenorex is a prodrug of amphetamine; upon ingestion, the compound will begin to metabolize into, as well as promote the production of, the active metabolites levoamphetamine and dextroamphetamine. Multiple sources have noted the substance as exerting "mild stimulant effects....[and having] relatively little abuse potential."